Strategic Partnerships Alterity’s lead asset ATH434 targets multiple Parkinsonian disorders with positive regulatory feedback for a Phase 3 program, creating opportunities for co-development, licensing, or commercialization partnerships with larger pharma or biotech.

Clinical Development Support The upcoming Phase 3 program and new Chief Medical Advisor appointment indicate readiness to partner on late-stage trials, with potential CRO, regulatory, and CMC services needs to support global trials.

Market Access Focus With a market where no approved therapies exist for Multiple System Atrophy and a commercial assessment underway, opportunities exist to collaborate on pricing, payer strategies, and real-world evidence to support market access.

Global Footprint Dual presence in Melbourne and San Francisco, plus a small but nimble team, suggests outsourcing alliances with regional CROs, clinical sites, and manufacturing partners to accelerate development and scale.

Platform Value Beyond ATH434, Alterity’s broad drug discovery platform and patentable compounds offer co-development or licensing opportunities to leverage the portfolio in neuroscience beyond the lead asset.